Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064064 · ClinicalTrials.gov registry record · Phase 2
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064064: Completed Phase 2 study, sponsored by Vion Pharmaceuticals.
NCT00064064 is a Phase 2 study that has completed, run by Vion Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064064, a Phase 2 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with 3-AP in treating patients who have metastatic non-small cell lung cancer.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG triapine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00064064 record still lists
NCT00064064 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00064064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00064064 about?
NCT00064064 is a clinical study titled "3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them m...
What is the current status of trial NCT00064064?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00064064?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00064064?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia